Generic Name and Formulations:
Silver sulfadiazine 1%; crm.
Par Pharmaceutical, Inc.
Indications for SSD:
Prophylaxis and treatment of sepsis in 2nd and 3rd degree burns.
Apply 1–2 times daily aseptically to approximately 1/16 inch depth to cleansed and debrided burns. Reapply promptly if removed. Continue until wound is healed. May be occluded.
Premature infants. Within first 2 months of birth. Late pregnancy.
G6PD deficiency. Impaired renal or hepatic function. Monitor serum sulfa levels and renal function in extensive burns. Pregnancy (Cat.B). Nursing mothers: not recommended.
Leukopenia increased with concomitant cimetidine. May inactivate debriding enzymes.
Transient leukopenia, skin necrosis, erythema multiforme, skin discoloration, burning sensation, rash, fungal overgrowth, interstitial nephritis, systemic sulfonamide reactions.
SSD—25g, 50g, 85g, 400g
SSD AF—50g, 400g
Neurology Advisor Articles
- Combined Exercise Training Increases BDNF in Relapsing-Remitting MS
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Apheresis Associated With Clinical Improvement in Early Active Multiple Sclerosis
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Surgical Outcomes Associated With Trigger Site Deactivation for Migraines
- A Convenient Truth: The Problem With Seizure Under-Reporting and How to Fix It
- Incidence of Serotonin Syndrome With Co-Prescription of Triptans, Antidepressants
- Idiopathic Parkinson Disease May Increase Risk for Overactive Bladder
- Palliative Care in Movement Disorders: Recommendations for Improvement
- Cannabinoids May Be Effective as Adjunctive Treatment for Refractory Epilepsy